OBJECTIVE: To explore the anti-inflammatory mechanisms of interleukin-4 (IL-4), interleukin-10 (IL-10) and interleukin-13 (IL-13) in acute respiratory distress syndrome (ARDS). METHODS: Enzyme-linked immunosorbent assay (ELISA) was employed to determine the plasma levels of IL-4, IL-10 and IL-13 in patients with ARDS (n = 22) and systemic inflammatory response syndrome (SIRS, n = 8). Ten normal subjects were enrolled as controls. RESULTS: The plasma levels of IL-4, IL-10 and IL-13 were (261 +/- 55) microg/L, (458 +/- 112) microg/L and (5.21 +/- 2.02) microg/L, respectively in patients with ARDS; (155 +/- 26) micro g/L, (260 +/- 54) microg/L and (1.69 +/- 0.39) microg/L respectively in patients with SIRS; and (43 +/- 13) microg/L, (135 +/- 15) microg/L and (0.33 +/- 0.10) microg/L, respectively in normal controls. They were significantly increased in patients with ARDS and SIRS as compared to normal controls, and the levels were higher in patients with ARDS than in patients with SIRS. CONCLUSIONS: Increased release of anti-inflammatory cytokines, such as IL-4, IL-10 and IL-13, may be one of the underlining mechanisms for the development of ARDS and SIRS.
OBJECTIVE: To explore the anti-inflammatory mechanisms of interleukin-4 (IL-4), interleukin-10 (IL-10) and interleukin-13 (IL-13) in acute respiratory distress syndrome (ARDS). METHODS: Enzyme-linked immunosorbent assay (ELISA) was employed to determine the plasma levels of IL-4, IL-10 and IL-13 in patients with ARDS (n = 22) and systemic inflammatory response syndrome (SIRS, n = 8). Ten normal subjects were enrolled as controls. RESULTS: The plasma levels of IL-4, IL-10 and IL-13 were (261 +/- 55) microg/L, (458 +/- 112) microg/L and (5.21 +/- 2.02) microg/L, respectively in patients with ARDS; (155 +/- 26) micro g/L, (260 +/- 54) microg/L and (1.69 +/- 0.39) microg/L respectively in patients with SIRS; and (43 +/- 13) microg/L, (135 +/- 15) microg/L and (0.33 +/- 0.10) microg/L, respectively in normal controls. They were significantly increased in patients with ARDS and SIRS as compared to normal controls, and the levels were higher in patients with ARDS than in patients with SIRS. CONCLUSIONS: Increased release of anti-inflammatory cytokines, such as IL-4, IL-10 and IL-13, may be one of the underlining mechanisms for the development of ARDS and SIRS.
Authors: B Guery; H Georges; M Labalette; O Leroy; T d'Escrivan; X Gonin; Y Mouton; J P Dessaint; Y Yazdanpanah Journal: Med Mal Infect Date: 2004-07 Impact factor: 2.152